Genus PLC
LSE:GNS

Watchlist Manager
Genus PLC Logo
Genus PLC
LSE:GNS
Watchlist
Price: 2 515 GBX -1.95% Market Closed
Market Cap: 1.7B GBX
Section:
 

Relative Value

The Relative Value of one GNS stock under the Base Case scenario is 3 109.62 GBX. Compared to the current market price of 2 515 GBX, Genus PLC is Undervalued by 19%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

GNS Relative Value
Base Case
3 109.62 GBX
Undervaluation 19%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

2.5
P/S
P/S
Price to Sales
2.5
vs History
52
vs Industry
78
Median 3Y
2.1
Median 5Y
2.6
Industry
8.2
Forward
2.3
More Details
86.1
P/E
P/E
Price to Earnings
86.1
vs History
15
vs Industry
5
Median 3Y
48.4
Median 5Y
56.9
Industry
24.2
Forward
26.3
More Details
24.7
P/OCF
P/OCF
Price to OCF
24.7
vs History
85
vs Industry
7
Median 3Y
27.5
Median 5Y
40.4
Industry
23
More Details
98.6
P/FCFE
P/FCFE
Price to FCFE
98.6
vs History
39
vs Industry
2
Median 3Y
96.5
Median 5Y
93
Industry
25.5
More Details
3.5
P/B
P/B
Price to Book Value
3.5
vs History
31
vs Industry
35
Median 3Y
2.6
Median 5Y
3.2
Industry
3.3
More Details
2.8
EV/S
EV/S
Enterprise Value to Sales
2.8
vs History
52
vs Industry
64
Median 3Y
2.4
Median 5Y
2.9
Industry
8.6
Forward
2.6
More Details
8.7
EV/GP
EV/GP
Enterprise Value to Gross Profit
8.7
vs History
4
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.5
More Details
16.7
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
16.7
vs History
58
vs Industry
10
Median 3Y
15.5
Median 5Y
17.3
Industry
6.1
Forward
14.5
More Details
27.6
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
27.6
vs History
63
vs Industry
6
Median 3Y
26.8
Median 5Y
30.2
Industry
6.6
Forward
20.8
More Details
28.2
EV/OCF
EV/OCF
Enterprise Value to OCF
28.2
vs History
90
vs Industry
5
Median 3Y
31.9
Median 5Y
45
Industry
8.8
More Details
39
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
39
vs History
63
vs Industry
3
Median 3Y
49.5
Median 5Y
50
Industry
6.8
More Details
2.5
EV/IC
EV/IC
Enterprise Value to IC
2.5
vs History
33
vs Industry
49
Median 3Y
1.7
Median 5Y
2.2
Industry
5.7
More Details

Multiples Across Competitors

GNS Competitors Multiples
Genus PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
Genus PLC
LSE:GNS
1.7B GBP 2.5 86.1 16.7 27.6
IL
Can Fite Biopharma Ltd
TASE:CANF
154.4T ILS 56 075 009.4 -3 850 870.8 -3 778 883.1 -3 770 471.4
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 079 720.5 -161 975.9 -196 690.4 -194 445.9
US
Abbvie Inc
NYSE:ABBV
386.7B USD 6.5 164.7 16 22.7
US
Amgen Inc
NASDAQ:AMGN
174B USD 4.8 24.8 18 18
US
Gilead Sciences Inc
NASDAQ:GILD
153.2B USD 5.3 18.9 12.7 12.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117.2B USD 10 31.9 23.4 24.4
US
Epizyme Inc
F:EPE
94.1B EUR 2 067.2 -527.5 -574.4 -559.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.5B USD 5.6 17.4 16.6 18.8
AU
CSL Ltd
ASX:CSL
83.9B AUD 3.6 18.7 12.6 15.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
49.1B USD 15.3 1 127.9 152 184.4
P/S Multiple
Revenue Growth P/S to Growth
UK
Genus PLC
LSE:GNS
Average P/S: 8 196 077.3
2.5
6%
0.4
IL
C
Can Fite Biopharma Ltd
TASE:CANF
56 075 009.4
140%
400 535.8
FR
Pharnext SCA
OTC:PNEXF
34 079 720.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.5
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.8
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.3
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10
10%
1
US
E
Epizyme Inc
F:EPE
2 067.2
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
6%
0.9
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
15.3
46%
0.3
P/E Multiple
Earnings Growth PEG
UK
Genus PLC
LSE:GNS
Average P/E: 186.3
86.1
59%
1.5
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -3 850 870.8 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 975.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
164.7
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.8
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.9
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.9
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -527.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.4
10%
1.7
AU
CSL Ltd
ASX:CSL
18.7
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 127.9
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
UK
Genus PLC
LSE:GNS
Average EV/EBITDA: 33.5
16.7
9%
1.9
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -3 778 883.1 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 690.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
18
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.4
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -574.4 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.6
11%
1.5
AU
CSL Ltd
ASX:CSL
12.6
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
152
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
UK
Genus PLC
LSE:GNS
Average EV/EBIT: 40.5
27.6
16%
1.7
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -3 770 471.4 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 445.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.7
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.4
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -559.1 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.8
13%
1.4
AU
CSL Ltd
ASX:CSL
15.7
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
184.4
N/A N/A

See Also

Summary
GNS intrinsic value, competitors valuation, and company profile.
DCF Valuation
GNS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
GNS stock valuation using valuation multiples.
Wall Street Estimates
GNS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
GNS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 309,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.